Quick Answer
Ovid Therapeutics Inc. reported Diluted EPS of $0.74 per share (loss) for fiscal year 2023.
Ovid Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2023 | -$0.74 | +3.9% |
| 2022 | -$0.77 | -143.8% |
| 2021 | $1.76 | +226.6% |
| 2020 | -$1.39 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$0.20 | -25.0% | -266.7% |
| June 30, 2024 | $0.12 | +166.7% | +170.6% |
| March 31, 2024 | -$0.17 | +10.5% | -6.3% |
| September 30, 2023 | -$0.16 | +5.9% | +11.1% |
| June 30, 2023 | -$0.18 | +14.3% | +5.3% |
| March 31, 2023 | -$0.19 | +17.4% | -11.8% |
| September 30, 2022 | -$0.17 | +0.0% | +19.0% |
| June 30, 2022 | -$0.21 | +8.7% | +8.7% |
- Ovid Therapeutics Inc. showed an increase of +3.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2023 period, Ovid Therapeutics Inc.’s diluted eps has grown by 46.8% (from $1.39 per share (loss) to $0.74 per share (loss)).
- The most recent figure is from Ovid Therapeutics Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 8, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: